HEREDITARY ANGIOEDEMA MARKET ANALYSIS

Hereditary Angioedema Market is segmented By Type (Hereditary Angioedema Type I and Hereditary Angioedema Type II), By Drug Class (C1 Esterase Inhibitor, Kallikrein Inhibitor, Bradykinin Receptor, Attenuated Androgens, and Others), By Route of Administration (Subcutaneous, Intravenous, and Oral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Published In : Nov 2024
Code : CMI1292
Pages :175
Formats :
Excel and PDF
Industry : Pharmaceutical

Key Takeaways from Analyst

The global hereditary angioedema market is expected to witness steady growth over the forecast period due to increasing disease awareness and diagnosis rates. The market currently has few approved treatment options and there remains a large unmet need. The launch of novel therapies with improved efficacy and convenience of administration could transform the treatment landscape.

Lack of disease awareness in developing countries may negatively impact the market growth. High unmet needs represent lucrative opportunities for leading pharmaceutical companies to develop novel treatment options and gain more market share. Development of subcutaneous and oral drugs with improved pharmacokinetics will augment patient adherence to treatment.

North America will likely continue dominating the market given the region's high healthcare spending and early adoption of new drugs. However, other developed markets in Europe and Asia Pacific are also expected to see faster growth.